Allergy Experience Study
Peanut Allergy
About this trial
This is an interventional basic science trial for Peanut Allergy focused on measuring food allergy, oral immunotherapy, mindsets, patient experience
Eligibility Criteria
Inclusion Criteria:
- peanut-specific blood IgE level >=60 Ku/L
- or, if IgE levels <60, need to have a skin prick test greater than 3mm and IgE >5 Ku/L
Exclusion Criteria:
- having previously participated in an OIT treatment or having a family member who had done so (since the study focused on educating participants about OIT)
- being in the updose phase of allergy shots or sublingual therapy
- having been intubated or admitted to an ICU because of allergic reaction
- having a heart disorder
- diagnosed eosinophilic esophagitis
- being on oral steroids or Xolair
- diagnosed anxiety disorders, as we expected this group to have higher baseline anxiety about treatment.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Symptoms as Side Effects Mindset
Symptoms as Positive Signals Mindset
Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that these non-life-threatening symptoms are an unfortunate part of treatment that must be endured, similar to side effects from common medications.
Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that symptoms are a sign that that their bodies are gradually increasing desensitization, similar to having sore muscles after a difficult workout.